on Nanohale AG (ETR:FYB)
Formycon Enhances Biosimilar Development with AI Technologies
Formycon AG, a leading developer of biosimilars based in Germany, is streamlining its biosimilar development process through the integration of digital technologies. As part of its FYB4GROWTH strategy, Formycon is focusing on artificial intelligence (AI) to enhance efficiency and competitiveness in clinical trials.
The company has implemented PhlexTMF Enterprise, a digital trial master file solution from Phlexglobal, which aids in regulatory compliance and documentation for clinical trials. This implementation aims to improve efficiency by 20% and support high standards of quality and data integrity.
Beyond PhlexTMF, Formycon is leveraging AI for analyzing manufacturing process data, further optimizing collaborations with contract manufacturers. These steps mark significant advancements in their approach to biosimilar development, underpinning Formycon's strategic emphasis on scientific excellence and innovation.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news